Reversal of Multidrug Resistance in Human Leukemia K562 by Tamolarizine, a Novel Calcium Antagonist

この論文にアクセスする

この論文をさがす

著者

抄録

A new type of organic Ca<SUP>2+</SUP> channel blocker, tamolarizine, was examined for its reversing effect on multidrug-resistant tumor cells.Tamolarizine synergistically potentiated the cytotoxicity of doxorubicin for doxorubicin-resistant K562 cells(K562/DXR)at a concentration of 0.1-10μM, but had hardly any synergistic effects in the parental cell line(K562)at the same concentration.Moreover, tamolarizine inhibits the P-glycoprotein pump-efflux activity in a dose-related manner and reduces the expression of the immunoreactive P-glycoprotein in K562/DXR cells as evaluated by cytofluorimetric assay.These results indicate that tamolarizine reverses the multidrug-resistance phenotype through direct interaction with P-gylcoprotein.

収録刊行物

  • The Japanese journal of pharmacology

    The Japanese journal of pharmacology 82(3), 265-268, 2000-03-01

    公益社団法人 日本薬理学会

参考文献:  15件中 1-15件 を表示

各種コード

  • NII論文ID(NAID)
    10008183653
  • NII書誌ID(NCID)
    AA00691188
  • 本文言語コード
    ENG
  • 資料種別
    SHO
  • ISSN
    00215198
  • NDL 記事登録ID
    5321105
  • NDL 雑誌分類
    ZS51(科学技術--薬学)
  • NDL 請求記号
    Z53-D199
  • データ提供元
    CJP書誌  NDL  J-STAGE 
ページトップへ